share_log
Benzinga ·  Oct 9 08:07
Windtree Therapeutics Shares Are Trading Higher After the Company Announced That the Trial Design of Its SEISMiC Phase 2b Has Been Published by the European Society of Cardiology Heart Failure
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment